Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir Cardiac Repolarization Study
NCT05905484Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and chronic hepatitis C (CHC) (4 arms), sponsored by Atea Pharmaceuticals. Primary endpoint: Placebo-corrected change-from-baseline QTc. Started Apr 2023; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT05905484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905484.